Continuation of Bevacizumab After Progression May Not Improve Survival Outcomes in NSCLC
AvaALL was the first phase 3 study to evaluate bevacizumab across multiple lines of treatment beyond progression in patients with non-small cell lung cancer.
AvaALL was the first phase 3 study to evaluate bevacizumab across multiple lines of treatment beyond progression in patients with non-small cell lung cancer.
The feasibility of lenalidomide in combination therapy for chronic lymphocytic leukemia is in question.
Capmatinib has demonstrated preclinical activity in EGFR-mutant and MET-activated non-small cell lung cancer when administered with concurrent EGFR-TKIs.
Researchers investigated cancer-related fatigue in 16 patients with multiple myeloma who were treated with bortezomib, lenalidomide, or thalidomide.
Radiotherapy after surgery may modify ipsilateral breast tumor recurrence risk among different subtypes of breast cancer.
The RESONATE-2 trial excluded certain patients with chronic lymphocytic leukemia, leaving the efficacy and tolerability of ibrutinib in this population unknown.
There is paucity of comparative and efficacy information on novel agents used as frontline induction therapies in multiple myeloma.
Evidence suggests that S-1 monotherapy may be safe and effective in non-small cell lung cancer.
Rituximab plus ibrutinib is the first nonchemotherapy combination regimen approved in Waldenström macroglobulinemia.
Whether radiofrequency ablation is a superior treatment option to lumpectomy requires further investigation.